Hydrocortisone Substipharm (Hydrocortisone)

Hydrocortisone Substipharm is indicated for several acute and chronic conditions where rapid glucocorticoid activity is required.

• Replacement therapy for adrenal insufficiency, including primary or secondary adrenal failure.
• Management of circulatory shock, especially when cortisol deficiency contributes to hemodynamic instability.
• Treatment of severe inflammatory or allergic reactions such as anaphylaxis, angioedema, or acute dermatitis.
• Control of acute asthma exacerbations that do not respond adequately to inhaled bronchodilators.
• Adjunctive therapy for severe sepsis or systemic inflammatory response syndrome when corticosteroid support is deemed appropriate.

• Hydrocortisone Substipharm acts as an agonist at intracellular glucocorticoid receptors. After crossing cell membranes, the drug‑receptor complex translocates to the nucleus, where it binds glucocorticoid response elements on DNA and modulates transcription of multiple genes. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of leukocyte migration, and suppression of immune cell activation, producing anti‑inflammatory and immunosuppressive effects, and contributes to metabolic regulation of glucose and electrolytes.

Systemic administration of hydrocortisone may be associated with a range of adverse reactions, varying from mild and transient to potentially life‑threatening.

Common

• Increased blood glucose levels and possible hyperglycemia.
• Fluid retention leading to peripheral edema or weight gain.
• Mood changes such as irritability, anxiety, or insomnia.
• Gastrointestinal discomfort, including dyspepsia or abdominal pain.
• Elevated blood pressure or hypertension.
• Skin thinning or easy bruising.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis, risking adrenal crisis on abrupt withdrawal.
• Severe infections or worsening of existing infections due to immunosuppression.
• Gastrointestinal bleeding or perforation, especially when combined with NSAIDs.

Before initiating therapy with Hydrocortisone Substipharm, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active systemic infections; glucocorticoids can exacerbate bacterial, viral, or fungal diseases.
• Monitor blood glucose and electrolytes regularly, especially in diabetic or renal‑impaired patients.
• Taper the dose gradually when discontinuing long‑term therapy to avoid adrenal insufficiency.
• Use with caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
• Evaluate cardiovascular status, as fluid retention may worsen hypertension or heart failure.
• Consider potential risks during pregnancy and lactation; data are limited, so benefits must outweigh uncertainties.

Hydrocortisone Substipharm can alter the pharmacokinetics or pharmacodynamics of other medicines, requiring attention to possible interactions.

Avoid

• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, which can increase hydrocortisone exposure.
• Live vaccines, because immunosuppression may reduce vaccine efficacy and increase infection risk.
• Concurrent systemic antifungal therapy for invasive fungal infections without dose adjustment.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which raise the risk of gastrointestinal ulceration or bleeding.
• Antidiabetic agents, as hydrocortisone may raise blood glucose and require dose modification.
• Antihypertensive medications, particularly diuretics or ACE inhibitors, due to potential fluid retention and blood pressure changes.
• Other corticosteroids, to avoid additive glucocorticoid effects and HPA‑axis suppression.